The PHLPP2 phosphatase is a druggable driver of prostate cancer progression.

Autor: Nowak DG; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY dgn2001@med.cornell.edu.; Division of Hematology and Medical Oncology, Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine, New York, NY., Katsenelson KC; Department of Pharmacology, University of California San Diego, La Jolla, CA., Watrud KE; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY., Chen M; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY., Mathew G; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY., D'Andrea VD; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY., Lee MF; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY., Swamynathan MM; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY., Casanova-Salas I; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY., Jibilian MC; Division of Hematology and Medical Oncology, Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine, New York, NY., Buckholtz CL; Division of Hematology and Medical Oncology, Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine, New York, NY., Ambrico AJ; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY., Pan CH; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY., Wilkinson JE; Department of Pathology, University of Michigan, Ann Arbor, MI., Newton AC; Department of Pharmacology, University of California San Diego, La Jolla, CA., Trotman LC; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY trotman@cshl.edu.

Publikováno v: The Journal of cell biology [J Cell Biol] 2019 Jun 03; Vol. 218 (6), pp. 1943-1957. Date of Electronic Publication: 2019 May 15.